187 related articles for article (PubMed ID: 22143520)
1. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir.
Yi G; Deval J; Fan B; Cai H; Soulard C; Ranjith-Kumar CT; Smith DB; Blatt L; Beigelman L; Kao CC
Antimicrob Agents Chemother; 2012 Feb; 56(2):830-7. PubMed ID: 22143520
[TBL] [Abstract][Full Text] [Related]
2. Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.
Eltahla AA; Tay E; Douglas MW; White PA
Antimicrob Agents Chemother; 2014 Dec; 58(12):7215-24. PubMed ID: 25246395
[TBL] [Abstract][Full Text] [Related]
3. Computational study on the drug resistance mechanism of HCV NS5B RNA-dependent RNA polymerase mutants V494I, V494A, M426A, and M423T to Filibuvir.
Wang H; Guo C; Chen BZ; Ji M
Antiviral Res; 2015 Jan; 113():79-92. PubMed ID: 25449363
[TBL] [Abstract][Full Text] [Related]
4. In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
Shi ST; Herlihy KJ; Graham JP; Fuhrman SA; Doan C; Parge H; Hickey M; Gao J; Yu X; Chau F; Gonzalez J; Li H; Lewis C; Patick AK; Duggal R
Antimicrob Agents Chemother; 2008 Feb; 52(2):675-83. PubMed ID: 18070954
[TBL] [Abstract][Full Text] [Related]
5. Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.
Fenaux M; Eng S; Leavitt SA; Lee YJ; Mabery EM; Tian Y; Byun D; Canales E; Clarke MO; Doerffler E; Lazerwith SE; Lew W; Liu Q; Mertzman M; Morganelli P; Xu L; Ye H; Zhang J; Matles M; Murray BP; Mwangi J; Zhang J; Hashash A; Krawczyk SH; Bidgood AM; Appleby TC; Watkins WJ
Antimicrob Agents Chemother; 2013 Feb; 57(2):804-10. PubMed ID: 23183437
[TBL] [Abstract][Full Text] [Related]
6. NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B.
Bessa LM; Launay H; Dujardin M; Cantrelle FX; Lippens G; Landrieu I; Schneider R; Hanoulle X
J Biol Chem; 2017 Nov; 292(44):18024-18043. PubMed ID: 28912275
[TBL] [Abstract][Full Text] [Related]
7. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.
Troke PJ; Lewis M; Simpson P; Gore K; Hammond J; Craig C; Westby M
Antimicrob Agents Chemother; 2012 Mar; 56(3):1331-41. PubMed ID: 22203605
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598.
Xue W; Jiao P; Liu H; Yao X
Antiviral Res; 2014 Apr; 104():40-51. PubMed ID: 24462692
[TBL] [Abstract][Full Text] [Related]
9. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor.
Jiang M; Zhang EZ; Ardzinski A; Tigges A; Davis A; Sullivan JC; Nelson M; Spanks J; Dorrian J; Nicolas O; Bartels DJ; Rao BG; Rijnbrand R; Kieffer TL
Antimicrob Agents Chemother; 2014 Sep; 58(9):5456-65. PubMed ID: 24982088
[TBL] [Abstract][Full Text] [Related]
10. Characterization of interactions between hepatitis C virus NS5B polymerase, annexin A2 and RNA - effects on NS5B catalysis and allosteric inhibition.
Solbak SMØ; Abdurakhmanov E; Vedeler A; Danielson UH
Virol J; 2017 Dec; 14(1):236. PubMed ID: 29228983
[TBL] [Abstract][Full Text] [Related]
11. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
Shi ST; Herlihy KJ; Graham JP; Nonomiya J; Rahavendran SV; Skor H; Irvine R; Binford S; Tatlock J; Li H; Gonzalez J; Linton A; Patick AK; Lewis C
Antimicrob Agents Chemother; 2009 Jun; 53(6):2544-52. PubMed ID: 19307358
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.
Howe AY; Cheng H; Johann S; Mullen S; Chunduru SK; Young DC; Bard J; Chopra R; Krishnamurthy G; Mansour T; O'Connell J
Antimicrob Agents Chemother; 2008 Sep; 52(9):3327-38. PubMed ID: 18559648
[TBL] [Abstract][Full Text] [Related]
13. Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.
Beaulieu PL
IDrugs; 2010 Dec; 13(12):938-48. PubMed ID: 21154154
[TBL] [Abstract][Full Text] [Related]
14. Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study.
Jiao P; Xue W; Shen Y; Jin N; Liu H
Mol Biosyst; 2014 Apr; 10(4):767-77. PubMed ID: 24452008
[TBL] [Abstract][Full Text] [Related]
15. Hydrogen/Deuterium Exchange Kinetics Demonstrate Long Range Allosteric Effects of Thumb Site 2 Inhibitors of Hepatitis C Viral RNA-dependent RNA Polymerase.
Deredge D; Li J; Johnson KA; Wintrode PL
J Biol Chem; 2016 May; 291(19):10078-88. PubMed ID: 27006396
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.
Wang C; Huang H; Valera L; Sun JH; O'Boyle DR; Nower PT; Jia L; Qiu D; Huang X; Altaf A; Gao M; Fridell RA
Antimicrob Agents Chemother; 2012 Mar; 56(3):1350-8. PubMed ID: 22214777
[TBL] [Abstract][Full Text] [Related]
17. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
Herlihy KJ; Graham JP; Kumpf R; Patick AK; Duggal R; Shi ST
Antimicrob Agents Chemother; 2008 Oct; 52(10):3523-31. PubMed ID: 18694956
[TBL] [Abstract][Full Text] [Related]
18. Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase.
Howe AY; Bloom J; Baldick CJ; Benetatos CA; Cheng H; Christensen JS; Chunduru SK; Coburn GA; Feld B; Gopalsamy A; Gorczyca WP; Herrmann S; Johann S; Jiang X; Kimberland ML; Krisnamurthy G; Olson M; Orlowski M; Swanberg S; Thompson I; Thorn M; Del Vecchio A; Young DC; van Zeijl M; Ellingboe JW; Upeslacis J; Collett M; Mansour TS; O'Connell JF
Antimicrob Agents Chemother; 2004 Dec; 48(12):4813-21. PubMed ID: 15561861
[TBL] [Abstract][Full Text] [Related]
19. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus.
Le Pogam S; Kang H; Harris SF; Leveque V; Giannetti AM; Ali S; Jiang WR; Rajyaguru S; Tavares G; Oshiro C; Hendricks T; Klumpp K; Symons J; Browner MF; Cammack N; Nájera I
J Virol; 2006 Jun; 80(12):6146-54. PubMed ID: 16731953
[TBL] [Abstract][Full Text] [Related]
20. Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase.
Winquist J; Abdurakhmanov E; Baraznenok V; Henderson I; Vrang L; Danielson UH
Antiviral Res; 2013 Mar; 97(3):356-68. PubMed ID: 23305851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
